# PIN in Combination With Sintilimab in Previously Treated pMMR/MSS CRC With Hepatic Metastases

> **NCT07411781** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Colorectal Cancer
- Adult

## Interventions

- **BIOLOGICAL:** PIN+sintilimab

## Key facts

- **NCT ID:** NCT07411781
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2027-03-31
- **Final completion:** 2031-03-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07411781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07411781, "PIN in Combination With Sintilimab in Previously Treated pMMR/MSS CRC With Hepatic Metastases". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07411781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*